2009.07.02 Weekly Broadcast Email
The following updates were made to the website for the week of June 29, 2009.
The following adverse events were reported during the month of June. A PDF of the AE document has been attached to this email and a summary of the event can be found on the adverse event page of the website.
98308: AE 25
98308 Announcement: (A Phase III Randomized, Double-Blind, Placebo Controlled Trial of North American Ginseng Extract (CVT-E002; COLD-fX®) to Prevent Respiratory Infection and Reduce Antibiotic Use in Patients with Chronic Lymphocytic Leukemia)
The accrual goal for 98308 has been achieved and the study closed, but follow-up is ongoing. The Data Management Center and site staff are working diligently together to collect quality data for all the patients who participated in this study. Your continued patience is appreciated as we work to enter the data sent to the Data Management Center. If you have questions regarding this process, please contact Cissy Yates at (336) 713-3172.
Accrual Totals for June:
In the month of June, 10 patients were accrued to CCCWFU CCOP Research Base trials. SCCC and Wake Forest were the top accruing sites with 3 patients each. See the Research Base home page for further information.
Featured Study: Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients
Have you considered opening 91105 at your site? Has your site accrued patients to this study recently? You might be interested to know…
Several recent protocol changes have been made to study 91105, Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients. These changes were made to facilitate and simplify enrollment which include:
-Adding a $40 gift for participating
-Simplifying and reducing medication exclusions
Visit the recently updated 91105 webpage to view:
• Letter from the PI, Dr. Steve Rapp
• Brochure outlining recent changes
• Training video
97106 (Randomized Study to Determine whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors) only has 13 minority accrual slots open for patient accruals. We would like to see this study close by the end of the summer, so if you have patients that may be eligible for this study, please try and get them registered by then.